Phase II study of PHA-848125AC as second line-treatment in pemetrexed pre-treated malignant pleural mesothelioma patients - ND

ERVIANO MEDICAL SCIENCES0 个研究点开始时间: 2009年3月12日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Signed and dated IRB/IEC-approved Informed Consent 2. Histologically or cytologically proven diagnosis of Malignant Pleural Mesothelioma (MPM), inoperable, in relapse after failure of prior pemetrexed-containing treatment (only one prior chemotherapy regimen allowed) 3. Presence of unidimensionally and/or bidimensionally measurable disease. Patients undergoing palliative radiation therapy for painful lesions are allowed to enter the study, provided that they have measurable disease outside the irradiated site. 4. No or asymptomatic pleural effusion. Patients with symptomatic pleural effusions can be enrolled provided that they have their effusions drained prior to enrollment on the clinical trial. 5. Age >/= 18 years 6. ECOG performance status 0-1 7. Estimated life expectancy of at least 3 months 8. Negative pregnancy test (if female in reproductive years) 9. Agreement upon the use of effective contraceptive methods (hormonal or barrier method of birth control, or abstinence) prior to study entry and for the duration of study participation, if men and women of child producing potential 10. Adequate liver function: - Bilirubin /= 3.0 g/dL - AST (SGOT), ALT (SGPT) /= 1,500 cells/mm3 - Platelet count >/= 100,000 cells/mm3 - Hemoglobin >/= 9.0 g/dL 13. At the time of start of treatment, at least 4 weeks must have elapsed since completion of prior chemotherapy, surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated) 14. With the exception of alopecia, resolution of all acute toxic effects of any prior chemotherapy, surgery or radiotherapy to NCI CTC (Version 3.0) grade Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis 2. Grade >1 retinopathy 3. Known brain metastases 4. Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment 5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy 6. Known infection with HIV, active hepatitis B or hepatitis C 7. Pregnant or breast feeding women 8. Previous (within the last 5 years) or current malignancies at other sites, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri 9. Current enrollment in or participation in another therapeutic clinical trial within 4 weeks preceeding treatment start 10. Diabetes mellitus uncontrolled 11. Gastrointestinal disease (e.g. Crohn?s disease, ulcerative colitis, or short gut syndrome) that would impact on drug absorption 12. Patients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baseline 13. Patients with previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson?s disease and extra-pyramidal syndromes 14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgement of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

研究者

发起方

ERVIANO MEDICAL SCIENCES

相似试验

进行中（未招募）

1 期

EUCTR2006-003772-35-FRerviano Medical Sciences S.r.l.232

进行中（未招募）

不适用

EUCTR2006-003772-35-NLerviano Medical Sciences s.r.l232

已完成

2 期

NL-OMON33846erviano Medical Sciences Srl, Italy28

进行中（未招募）

1 期

Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers. - not availableAdvanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung, non small cell lung and squamous non small cell lung cancers.MedDRA version: 13.1Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10033610Term: Pancreatic carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2006-003772-35-GBerviano Medical Sciences S.r.l.224

进行中（未招募）

不适用

Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers. - NDTreatment of patients with breast, ovarian, pancreatic, colorectal, small and non-small cell lung cancers.MedDRA version: 6.1Level: SOCClassification code 10029104

EUCTR2006-003772-35-ITERVIANO MEDICAL SCIENCES232